Herantis Pharma Oyj (HRTIS.HE)
EUR 1.42
(-1.73%)
EUR 1.42
(-1.73%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 34.82 Thousand EUR | -99.23% |
| 2022 | 454.11 Million EUR | 6206.81% |
| 2021 | 7.2 Million EUR | -0.08% |
| 2020 | 7.2 Million EUR | -0.08% |
| 2019 | 7.21 Million EUR | 12.93% |
| 2018 | 6.38 Million EUR | -2.8% |
| 2017 | 6.56 Million EUR | -19.1% |
| 2016 | 8.12 Million EUR | 5.13% |
| 2015 | 7.72 Million EUR | 18.48% |
| 2014 | 6.51 Million EUR | 252.32% |
| 2013 | 1.85 Million EUR | 10.21% |
| 2012 | 1.67 Million EUR | 34.58% |
| 2011 | 1.24 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 30 Thousand EUR | -13.85% |
| 2024 Q2 | 30 Thousand EUR | 0.0% |
| 2023 Q2 | 4.54 Million EUR | 0.0% |
| 2023 FY | 34.82 Thousand EUR | -99.99% |
| 2023 Q3 | 34.82 Thousand EUR | -99.23% |
| 2023 Q4 | 34.82 Thousand EUR | 0.0% |
| 2023 Q1 | 4.54 Million EUR | -0.0% |
| 2022 Q4 | 454.11 Million EUR | 9900.0% |
| 2022 Q3 | 4.54 Million EUR | -36.93% |
| 2022 FY | 454.11 Million EUR | 6206.81% |
| 2022 Q1 | 7.2 Million EUR | -0.0% |
| 2022 Q2 | 7.2 Million EUR | 0.0% |
| 2021 Q2 | 7.2 Million EUR | 0.0% |
| 2021 Q4 | 7.2 Million EUR | 0.0% |
| 2021 Q3 | 7.2 Million EUR | 0.0% |
| 2021 FY | 7.2 Million EUR | -0.08% |
| 2021 Q1 | 7.2 Million EUR | -0.08% |
| 2020 Q2 | 7.2 Million EUR | 0.0% |
| 2020 FY | 7.2 Million EUR | -0.08% |
| 2020 Q1 | 7.2 Million EUR | -0.08% |
| 2020 Q4 | 7.2 Million EUR | 0.0% |
| 2020 Q3 | 7.2 Million EUR | 0.0% |
| 2019 Q1 | 6.63 Million EUR | 3.93% |
| 2019 Q2 | 6.63 Million EUR | 0.0% |
| 2019 FY | 7.21 Million EUR | 12.93% |
| 2019 Q4 | 7.21 Million EUR | 0.0% |
| 2019 Q3 | 7.21 Million EUR | 8.66% |
| 2018 Q3 | 6.38 Million EUR | 3.85% |
| 2018 Q2 | 6.14 Million EUR | 0.0% |
| 2018 Q1 | 6.14 Million EUR | -6.4% |
| 2018 FY | 6.38 Million EUR | -2.8% |
| 2018 Q4 | 6.38 Million EUR | 0.0% |
| 2017 Q1 | 8.38 Million EUR | 3.26% |
| 2017 FY | 6.56 Million EUR | -19.1% |
| 2017 Q2 | 8.38 Million EUR | 0.0% |
| 2017 Q4 | 6.56 Million EUR | 0.0% |
| 2017 Q3 | 6.56 Million EUR | -21.65% |
| 2016 Q4 | 8.12 Million EUR | 0.0% |
| 2016 Q1 | 7.72 Million EUR | 0.0% |
| 2016 Q2 | 7.72 Million EUR | 0.0% |
| 2016 FY | 8.12 Million EUR | 5.13% |
| 2016 Q3 | 8.12 Million EUR | 5.13% |
| 2015 Q1 | 6.85 Million EUR | 5.12% |
| 2015 FY | 7.72 Million EUR | 18.48% |
| 2015 Q3 | 7.72 Million EUR | 12.71% |
| 2015 Q4 | 7.72 Million EUR | 0.0% |
| 2015 Q2 | 6.85 Million EUR | 0.0% |
| 2014 Q2 | 6.26 Million EUR | 231.26% |
| 2014 Q3 | 6.51 Million EUR | 4.04% |
| 2014 FY | 6.51 Million EUR | 252.32% |
| 2014 Q4 | 6.51 Million EUR | 0.0% |
| 2014 Q1 | 1.89 Million EUR | 2.23% |
| 2013 Q3 | 1.85 Million EUR | 0.0% |
| 2013 Q4 | 1.85 Million EUR | 0.0% |
| 2013 FY | 1.85 Million EUR | 10.21% |
| 2013 Q1 | 1.67 Million EUR | 0.0% |
| 2012 FY | 1.67 Million EUR | 34.58% |
| 2011 FY | 1.24 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Biohit Oyj | 700 Thousand EUR | 95.026% |
| Nanoform Finland Oyj | 6.25 Million EUR | 99.444% |